GenScript Biotech extends gain to hit near 5-year peak on Eli Lilly deal
BUZZ-GenScript Biotech extends gain to hit near 5-year peak on Eli Lilly deal ** Shares of GenScript Biotech Corp 1548.HK jump 8.2% to HK$40.28, their highest level since December 2021
** Stock extends a rally from the previous session after announcement of collaboration with Eli Lilly and Company LLY.N
** Stock third-biggest pct gainer in the Hang Seng Biotech Index .HSBIO, which climbs 1.8%
** GenScript shares closed 14.3% higher on Thursday in their best day since August 7, after co announced collaboration with Lilly TuneLab, the AI/machine learning-based drug discovery collaboration platform of Eli Lilly
** GenScript will provide wet lab services to TuneLab member companies to generate experimental data and translate AI generated predictions into biological evidence
** YTD, stock up 216.3%, Hang Seng Biotech Index .HSBIO up 11.2%
(Reporting by Donny Kwok)
Recent news on Genscript Biotech
See all newsBrief: Genscript Launches Life Sciences Startup Pitchfest With Nvidia For Biotech Innovation
GenScript Biotech extends gain to hit near 5-year peak on Eli Lilly deal
GenScript Biotech hits near 5-year high on Eli Lilly collaboration
Brief: ProBio & Kun Tuo Announce Strategic Collaboration To Deliver Integrated CDMO-CRO Solutions
HK-listed GenScript Biotech drops on discounted share sale